Ollin Biosciences Reported Positive JADE Study Results
The experimental drug OLN324 showed vision gains and durability in treating macular degeneration during clinical testing.
Updated on Sept. 23, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies to accurately represent the efficacy of new clinical drug trials?
Ollin Biosciences released proof-of-concept trial data for OLN324, a dual VEGF and Ang-2 inhibitor. The JADE study showed positive outcomes for patients with neovascular age-related macular degeneration and diabetic macular edema.
Why it matters
The study highlights a potential advancement in treatment durability for retinal diseases, as patients treated with the new drug required fewer interventions. This may offer a new therapeutic path for managing chronic vision-threatening conditions.
The JADE study evaluated 2 mg and 4 mg doses of the VEGF and Ang-2 inhibitor OLN324 in patients with retinal conditions. Researchers observed vision gains across all study arms through week 20 of the trial.
The players
Ollin Biosciences
This is a biotechnology company focused on developing novel therapeutics for ocular diseases.
The details
OLN324 demonstrated a superior reduction in pigment epithelial detachment thickness compared to faricimab. Additionally, the drug achieved fluid resolution comparable to faricimab at the 12-week mark for patients diagnosed with diabetic macular edema.
Timeline
At week 12, 82% of treated patients required no further re-treatment.
Vision gains were observed across all study arms through week 20.
The Tech Race
The development of dual-action inhibitors like OLN324 represents an evolution from older, single-target therapies in retinal medicine. By matching or exceeding the performance of current standards like faricimab, these drugs aim to reduce treatment burdens for patients.
For patients with macular degeneration, this drug could eventually mean fewer clinical visits for injections due to the observed treatment durability. This shift in therapeutic frequency could significantly improve the quality of life and routine management for those affected by retinal conditions.
The takeaway
The successful trial of OLN324 suggests that targeting multiple pathways, specifically VEGF and Ang-2, may provide better clinical outcomes for retinal patients. Patients should continue to consult with their ophthalmologists regarding the most current, evidence-based treatment options available.
Further reading
Learn more about the latest industry advancements in the Biotech section.
Live Poll
Do you trust pharmaceutical companies to accurately represent the efficacy of new clinical drug trials?
